Merck (MRK) stock in focus as its lung disease drug Winrevair gains FDA priority review for a label update based on Phase 3 ...

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving regulatory approvals and fulfilling customary ...

Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

Merck's Winrevair gains FDA priority review for PAH label update after ZENITH trial shows major reduction in serious events and strong clinical impact.

US pharma giant Merck & Co today revealed that the US Food and Drug Administration (FDA) has accepted and granted priority ...

The partners will use UNP's AI-based macrocycle discovery platform to develop synthetic peptide therapeutics for multiple ...

This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.

Merck Foundation Chairman, CEO with First Ladies of Africa & Asia at 7th Edition of Merck Foundation First Ladies Initiative ...

China has rapidly emerged as a global force in oncology, contributing a significant share of next-generation immunotherapies ...

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

Verizon Communications Inc. stands out as the top Dow dividend pick with strong cash flow and value potential. Click for my ...